TWI688571B - 化合物(四) - Google Patents

化合物(四) Download PDF

Info

Publication number
TWI688571B
TWI688571B TW104138186A TW104138186A TWI688571B TW I688571 B TWI688571 B TW I688571B TW 104138186 A TW104138186 A TW 104138186A TW 104138186 A TW104138186 A TW 104138186A TW I688571 B TWI688571 B TW I688571B
Authority
TW
Taiwan
Prior art keywords
general formula
alkyl
compound
group
halogen
Prior art date
Application number
TW104138186A
Other languages
English (en)
Chinese (zh)
Other versions
TW201632539A (zh
Inventor
亞歷山大 韋茅斯威爾遜
蘇菲亞 科姆斯塔
詹姆斯 博伊德爾
蘿拉 沃利斯
尤恩 大衛斯
卡爾 奧圖爾
羅布 克拉克森
Original Assignee
英商Nzp英國有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1420594.2A external-priority patent/GB201420594D0/en
Priority claimed from GBGB1420593.4A external-priority patent/GB201420593D0/en
Priority claimed from GBGB1505675.7A external-priority patent/GB201505675D0/en
Application filed by 英商Nzp英國有限公司 filed Critical 英商Nzp英國有限公司
Publication of TW201632539A publication Critical patent/TW201632539A/zh
Application granted granted Critical
Publication of TWI688571B publication Critical patent/TWI688571B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J9/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW104138186A 2014-11-19 2015-11-19 化合物(四) TWI688571B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB1420593.4 2014-11-19
GBGB1420594.2A GB201420594D0 (en) 2014-11-19 2014-11-19 Compounds
GBGB1420593.4A GB201420593D0 (en) 2014-11-19 2014-11-19 Compounds
GB1420594.2 2014-11-19
GB1505675.7 2015-04-01
GBGB1505675.7A GB201505675D0 (en) 2015-04-01 2015-04-01 Compounds

Publications (2)

Publication Number Publication Date
TW201632539A TW201632539A (zh) 2016-09-16
TWI688571B true TWI688571B (zh) 2020-03-21

Family

ID=54704022

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104138186A TWI688571B (zh) 2014-11-19 2015-11-19 化合物(四)

Country Status (10)

Country Link
US (2) US20170327531A1 (cg-RX-API-DMAC7.html)
EP (1) EP3221334B1 (cg-RX-API-DMAC7.html)
JP (1) JP6698085B2 (cg-RX-API-DMAC7.html)
KR (1) KR102527821B1 (cg-RX-API-DMAC7.html)
CN (1) CN107207558B (cg-RX-API-DMAC7.html)
CA (1) CA2968310A1 (cg-RX-API-DMAC7.html)
EA (1) EA033603B1 (cg-RX-API-DMAC7.html)
MX (1) MX381239B (cg-RX-API-DMAC7.html)
TW (1) TWI688571B (cg-RX-API-DMAC7.html)
WO (1) WO2016079520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170327531A1 (en) 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
JP6724004B2 (ja) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドFXRモジュレーター製造のための中間体としての5β−6−アルキル−7−ヒドロキシ−3−オンステロイド
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
KR20180095070A (ko) * 2015-12-22 2018-08-24 인터셉트 파마슈티컬즈, 인크. 오베티콜산의 다형성 결정질 형태들
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608777D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
GB201608776D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
CN106046093A (zh) * 2016-05-30 2016-10-26 华东师范大学 一种石胆酸的合成方法
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CN111285914B (zh) * 2018-12-10 2023-02-17 江西青峰药业有限公司 一种奥贝胆酸的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200736271A (en) * 2006-01-12 2007-10-01 Mitsubishi Chem Corp Process for production of steroids
CN101203526A (zh) * 2005-05-19 2008-06-18 伊莱吉尔瑞公司 制备3α(β)-7α(β)-二羟基-6α(β)-烷基-5β-胆烷酸的方法
CN102282157A (zh) * 2008-11-19 2011-12-14 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624748A (en) 1950-09-09 1953-01-06 Upjohn Co Bisnorchola-4, 6-dien-3-one-22-al
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル リサーチ ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
WO1994019366A1 (en) 1993-02-26 1994-09-01 Magainin Pharmaceuticals Inc. Chemical synthesis of squalamine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE60205891T2 (de) 2001-03-12 2006-06-22 Intercept Pharmaceuticals, Inc. Steroide als agonisten für fxr
US20090062256A1 (en) 2001-06-01 2009-03-05 Bristol-Myers Squibb Pharma Company LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
WO2003040211A2 (en) 2001-11-07 2003-05-15 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
CA2642220A1 (en) 2006-02-14 2007-08-23 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
EP2040713B1 (en) 2006-06-27 2014-06-18 Intercept Pharmaceuticals Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
CN101679476B (zh) 2007-01-19 2014-05-07 英特塞普特医药品公司 23取代的胆汁酸作为tgr5调节剂及其使用方法
AU2009276507B2 (en) * 2008-07-30 2015-11-19 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CN102325784B (zh) 2008-11-19 2014-11-19 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
CN102482315A (zh) 2009-07-29 2012-05-30 芝加哥大学 肝x受体激动剂
CN104781272A (zh) 2012-06-19 2015-07-15 英特塞普特医药品公司 奥贝胆酸的制备、用途和固体形式
US9777038B2 (en) 2012-10-26 2017-10-03 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
AU2013352288B2 (en) * 2012-11-28 2017-11-23 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
EA030152B1 (ru) 2013-05-14 2018-06-29 Интерсепт Фармасьютикалз, Инк 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов
CN105392780A (zh) 2013-05-24 2016-03-09 雀巢产品技术援助有限公司 用于预测肠易激综合征诊断的途径特异性测定
US10166246B2 (en) * 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
ES2938874T3 (es) 2014-05-29 2023-04-17 Bar Pharmaceuticals S R L Derivados de colano para su uso en el tratamiento y/o prevención de enfermedades mediadas por FXR y TGR5/GPBAR1
CA2966885A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
CN107207559B (zh) 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
CN107108688B (zh) 2014-11-19 2019-10-29 Nzp英国有限公司 作为制备类固醇FXR调节剂的中间体的6α-烷基-3,7-二酮类固醇
US20170327531A1 (en) 2014-11-19 2017-11-16 NZP UK Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
JP6724004B2 (ja) 2014-11-19 2020-07-15 エヌゼットピー ユーケー リミテッド ステロイドFXRモジュレーター製造のための中間体としての5β−6−アルキル−7−ヒドロキシ−3−オンステロイド
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
US10519191B2 (en) 2014-11-26 2019-12-31 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
WO2016086134A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
CN106279328A (zh) 2015-05-20 2017-01-04 重庆药友制药有限责任公司 一种制备6α-烷基鹅去氧胆酸的方法
TW201700447A (zh) 2015-06-19 2017-01-01 英特賽普醫藥品公司 Tgr5調控劑及其用法
CN106397522A (zh) 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二(叔丁基二甲基硅基氧基)‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN106478759A (zh) 2015-08-31 2017-03-08 陕西合成药业股份有限公司 奥贝胆酸衍生物及其制备方法和用途
CN106478756A (zh) 2015-09-02 2017-03-08 中美华世通生物医药科技(武汉)有限公司 Oca-e单晶及其制备方法和用途
CN106518946A (zh) 2015-09-10 2017-03-22 上海迪诺医药科技有限公司 磺酰脲衍生物、其药物组合物及应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101203526A (zh) * 2005-05-19 2008-06-18 伊莱吉尔瑞公司 制备3α(β)-7α(β)-二羟基-6α(β)-烷基-5β-胆烷酸的方法
TW200736271A (en) * 2006-01-12 2007-10-01 Mitsubishi Chem Corp Process for production of steroids
CN102282157A (zh) * 2008-11-19 2011-12-14 英特塞普特医药品公司 G蛋白偶联受体5(tgr5)调节剂及其使用方法
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists

Also Published As

Publication number Publication date
US20170327531A1 (en) 2017-11-16
EP3221334B1 (en) 2020-02-19
CN107207558B (zh) 2019-10-29
HK1244286A1 (en) 2018-08-03
CN107207558A (zh) 2017-09-26
US10597423B2 (en) 2020-03-24
TW201632539A (zh) 2016-09-16
CA2968310A1 (en) 2016-05-26
US20190077827A1 (en) 2019-03-14
EA033603B1 (ru) 2019-11-08
KR102527821B1 (ko) 2023-05-02
MX2017006567A (es) 2018-01-26
MX381239B (es) 2025-03-12
JP2017534669A (ja) 2017-11-24
WO2016079520A1 (en) 2016-05-26
JP6698085B2 (ja) 2020-05-27
EP3221334A1 (en) 2017-09-27
KR20170099896A (ko) 2017-09-01
EA201790885A1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
TWI688571B (zh) 化合物(四)
TWI690536B (zh) 化合物(一)
TWI686400B (zh) 化合物(二)
TWI686401B (zh) 化合物(三)
HK1244285A1 (en) 5.beta -6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators
HK1244286B (en) 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
HK1244287B (en) 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators
HK1246801B (en) 6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators